国际生物医学工程杂志
國際生物醫學工程雜誌
국제생물의학공정잡지
INTERNATIONAL JOURNAL OF BIOMEDICAL ENGINEERING
2011年
3期
154-157,166,后插2
,共6页
新型卟啉类光敏药物%光动力学疗法%HGC27和MGC803肿瘤细胞%细胞内定位
新型卟啉類光敏藥物%光動力學療法%HGC27和MGC803腫瘤細胞%細胞內定位
신형계람류광민약물%광동역학요법%HGC27화MGC803종류세포%세포내정위
PDT drug%Photodynamic therapy%HGC27 and MGC803 tumor cells%Porphyrin
目的 观察本实验室自行合成的新型卟啉类光敏药物对2种人胃癌细胞HGC27和MGC803的光动力学治疗(PDT)作用及作用机制.方法 以人胃癌细胞HGC27和MGC803为实验细胞株.实验分为4组:空白对照组(无药物孵育、无光照),单纯光敏药物组(药物孵育、无光照),单纯光照组(无药物孵育、有光照),光敏药物+光照组(药物孵育,同时有光照).本实验采用光漂白法(bleaching法)测定了该新型光敏药物随着光照时间延长自身的稳定性;采用MTT法检测了光动力学作用后肿瘤细胞的存活率;通过共聚焦激光显微镜(LSCM)观察了该光敏药物在HGC27和MGC803细胞内的具体定位(线粒体或者溶酶体).结果 随着光照时间的延长,该新型卟啉类光敏药物自身稳定性较好;无光照条件下对HGC27和MGC803细胞生长无任何影响(P>0.05);光照存在时对HGC27和MGC803细胞具有强烈的杀伤作用(P<0.05),且在浓度为3.125μmol/L时对于2种细胞的杀伤作用即达到最大;单纯光照对2种肿瘤细胞生长无任何影响;该光敏药物均定位于HGC27和MGC803细胞溶酶体内.结论 对于HGC27和MGC803胃癌细胞,该新型卟啉类光敏药物是一种很好的光动力治疗药物.
目的 觀察本實驗室自行閤成的新型卟啉類光敏藥物對2種人胃癌細胞HGC27和MGC803的光動力學治療(PDT)作用及作用機製.方法 以人胃癌細胞HGC27和MGC803為實驗細胞株.實驗分為4組:空白對照組(無藥物孵育、無光照),單純光敏藥物組(藥物孵育、無光照),單純光照組(無藥物孵育、有光照),光敏藥物+光照組(藥物孵育,同時有光照).本實驗採用光漂白法(bleaching法)測定瞭該新型光敏藥物隨著光照時間延長自身的穩定性;採用MTT法檢測瞭光動力學作用後腫瘤細胞的存活率;通過共聚焦激光顯微鏡(LSCM)觀察瞭該光敏藥物在HGC27和MGC803細胞內的具體定位(線粒體或者溶酶體).結果 隨著光照時間的延長,該新型卟啉類光敏藥物自身穩定性較好;無光照條件下對HGC27和MGC803細胞生長無任何影響(P>0.05);光照存在時對HGC27和MGC803細胞具有彊烈的殺傷作用(P<0.05),且在濃度為3.125μmol/L時對于2種細胞的殺傷作用即達到最大;單純光照對2種腫瘤細胞生長無任何影響;該光敏藥物均定位于HGC27和MGC803細胞溶酶體內.結論 對于HGC27和MGC803胃癌細胞,該新型卟啉類光敏藥物是一種很好的光動力治療藥物.
목적 관찰본실험실자행합성적신형계람류광민약물대2충인위암세포HGC27화MGC803적광동역학치료(PDT)작용급작용궤제.방법 이인위암세포HGC27화MGC803위실험세포주.실험분위4조:공백대조조(무약물부육、무광조),단순광민약물조(약물부육、무광조),단순광조조(무약물부육、유광조),광민약물+광조조(약물부육,동시유광조).본실험채용광표백법(bleaching법)측정료해신형광민약물수착광조시간연장자신적은정성;채용MTT법검측료광동역학작용후종류세포적존활솔;통과공취초격광현미경(LSCM)관찰료해광민약물재HGC27화MGC803세포내적구체정위(선립체혹자용매체).결과 수착광조시간적연장,해신형계람류광민약물자신은정성교호;무광조조건하대HGC27화MGC803세포생장무임하영향(P>0.05);광조존재시대HGC27화MGC803세포구유강렬적살상작용(P<0.05),차재농도위3.125μmol/L시대우2충세포적살상작용즉체도최대;단순광조대2충종류세포생장무임하영향;해광민약물균정위우HGC27화MGC803세포용매체내.결론 대우HGC27화MGC803위암세포,해신형계람류광민약물시일충흔호적광동력치료약물.
Objective To explore photodynamic therapeutic efficiency and related mechanisms of a new porphyrin-typed photodynamic therapy (PDT) drug synthesized in our lab on HGC27 and MGC803 cells.Methods Two different kinds of gastric cancer cells, HGC27 and MGC803, were chosen as cell lines to evaluate the PDT efficiency of new porphyrin-typed PDT drug based upon four group experiments: control (no drug, no light) group, drug treated group (only drug, no light), light treated group (no drug, only light) and experiment group (with drug and light at the same time). Bleaching method was used to evaluate the photostability of new porphyrin-typed PDT drug upon repititive illumination. MTT assay was carried out to test the survival rate of tumor cells after PDT. Cofocal laser scanning microscope (CLSM) was applied to observe subcellular localization of drug in HGC27 and MGC803 cells (mitochondria and lysosome). Results New porphyrin-typed PDT drug has good stability to light, no toxicity on HGC27 and MGC803 cells without light (P>0.05), while intense lethal effect was observed upon light illumination (P<0.05). The peak efficacy appeared when concentration is 3.12 μmol/L for both HGC27 and MGC803 cells and the new porphyrin-typed PDT drug localizes in lysosome other than traditional mitochondrion. Conclusion New porphyrin-typed PDT drug is a good photodynamic therapeutic sensitizer for HGC27 and MGC803 tumor cells.
